![]() ![]() Rumpus had focused on applying it to vEDS. The investigators behind that study determined that this signaling pathway represented “unanticipated therapeutic opportunities.”ĭenovo had licensed DB102 to Rumpus Therapeutics for select medical indications. ![]() One recent study found that mice carrying vEDS-associated mutations in their equivalent of the CO元A1 gene had abnormal PKC beta signaling, resulting in the easily ruptured blood vessels characteristic of the disorder. ![]() A signaling pathway works somewhat like an electrical circuit, where a signal at one end causes a reaction at the other end. Serine-threonine kinases are central to a number of cellular signaling pathways, some of which appear altered in vEDS. Haller, PhD, Denovo’s chief business officer, said in a press release.Īlso known as AR101, DB102 is an orally delivered, experimental small molecule that inhibits a type of enzyme called a serine-threonine kinase. “DB102 has the potential to treat a variety of disorders, both inside and outside of the oncology field,” Michael F. Aytu BioPharma has acquired the option to license DB102 (enzastaurin), an investigational anti-tumor therapy with the potential to treat vascular Ehlers-Danlos syndrome, or vEDS.ĭenovo Biopharma, which holds worldwide rights to DB102 - originally developed as an oncology treatment - will continue to develop the oral therapy for certain cancers. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |